Louis Brenner

Louis Brenner, M.D. joined Hopewell as our President and Chief Executive Officer and a Member of our Board of Directors in November of 2022. 

 

Over his twenty-year career in the biotechnology industry, Dr. Brenner has provided entrepreneurial leadership to companies focused on the development of novel technologies and products to benefit patients with unmet clinical needs. His expertise in scientific and clinical development strategy, corporate and organizational development, and fundraising will help position Hopewell to capitalize on our potential to provide innovative technology to the rapidly evolving field of genomic medicine. Dr. Brenner has built and guided scientific, clinical, and corporate organizations that have successfully navigated all aspects of the product development cycle from preclinical research to IND to Phase 3 Trials to Regulatory Approvals and product launches. 

​

Before joining Hopewell, Dr. Brenner was President and CEO of Allena Pharmaceuticals where he catalyzed the company’s progression from a private, early-stage to a public, late-stage development company with multiple homegrown assets in Phase 2 and Phase 3 development. At Allena, he completed multiple financings including a crossover round, an IPO, and multiple secondary offerings. Previously, he served as Chief Medical Officer for Idera Pharmaceuticals, where he assembled a development stage portfolio of nucleic acid therapeutics for cancer and autoimmune diseases, and as Chief Medical officer of Radius Health, where he supervised the successful Phase 3 Global Osteoporosis program for abaloparatide, now marketed as Tymlos. As Senior Vice President at AMAG Pharmaceuticals, he oversaw the Phase 3 program, regulatory filing, and launch of the IV iron product Feraheme. At Genzyme, he was a key member of the management teams of the Renal and Transplant Business Units, where he contributed to the success of the blockbuster hyperphosphatemia Renagel/Renvela franchise and led the acquisitions of Bone Care International and Anormed, which brought the additional products of Hectorol for metabolic bone disease and Mozobil for stem cell mobilization to the company’s portfolio. He has previously served as Chairman of the Board of the National Kidney Foundation Affiliate for the New England region and as a Director for PLC Medical Systems and Goldfinch Bio. 

​

Dr. Brenner earned a B.S. in Biology from Yale University, an M.D. from Duke University and an M.B.A. from Harvard Business School. He completed his residency in internal medicine at Brigham and Women’s Hospital and his fellowship in nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital. Dr. Brenner holds clinical appointments at Brigham and Women’s Hospital and Dana Farber Cancer Institute.